Mucosal vaccination against encapsulated respiratory bacteria--new potentials for conjugate vaccines?

2.50
Hdl Handle:
http://hdl.handle.net/2336/4606
Title:
Mucosal vaccination against encapsulated respiratory bacteria--new potentials for conjugate vaccines?
Authors:
Jakobsen, H; Jonsdottir, I
Citation:
Scand. J. Immunol. 2003, 58(2):119-28
Issue Date:
1-Aug-2003
Abstract:
Polysaccharide (PS)-encapsulated bacteria such as Haemophilus influenzae type b (Hib), Streptococcus pneumoniae (pneumococcus), Neisseria meningitides (meningococcus) and group B streptococcus (GBS), cause a major proportion of disease in early childhood. Native PS vaccines are immunogenic and provide protection against disease in healthy adults but do not induce immunological memory. PSs are T-cell-independent antigens and do not elicit antibodies in infants and young children, but by conjugating PS to proteins they become T-cell dependent and immunogenic at an early age. Despite excellent efficacy of PS-protein conjugate vaccines against invasive disease, protection against mucosal infections such as pneumococcal otitis media has been less efficacious. Circulating PS-specific antibodies may protect against infections at mucosal sites, but mucosal immunoglobulin A antibodies may also contribute significantly to protection against mucosal infections. Mucosal immunization of experimental animals with conjugate vaccines against Hib, pneumococcus, meningococcus and GBS induces systemic and mucosal immune responses, which provide protection against carriage, otitis media and invasive disease in a variety of challenge models, providing new means for protection against encapsulated bacteria. In addition, mucosal immunization of neonatal mice with a pneumococcal conjugate and the nontoxic adjuvant LT-K63 has been superior to parenteral immunization in eliciting protective antibodies and PS-specific memory, and thus circumventing the limitations of antibody responses to PS that are responsible for enhanced susceptibility of neonates and infants to infections caused by encapsulated bacteria. Through T-cell dependent enhanced immunogenicity of PS-protein conjugate vaccines, mucosal immunization could be an attractive approach for early life immunization against encapsulated bacteria.
Additional Links:
http://www.blackwell-synergy.com/doi/full/10.1046/j.1365-3083.2003.01292.x

Full metadata record

DC FieldValue Language
dc.contributor.authorJakobsen, H-
dc.contributor.authorJonsdottir, I-
dc.date.accessioned2006-09-25T16:09:02Z-
dc.date.available2006-09-25T16:09:02Z-
dc.date.issued2003-08-01-
dc.identifier.citationScand. J. Immunol. 2003, 58(2):119-28en
dc.identifier.issn0300-9475-
dc.identifier.pmid12869132-
dc.identifier.doidoi:10.1046/j.1365-3083.2003.01292.x-
dc.identifier.otherAAI12-
dc.identifier.urihttp://hdl.handle.net/2336/4606-
dc.description.abstractPolysaccharide (PS)-encapsulated bacteria such as Haemophilus influenzae type b (Hib), Streptococcus pneumoniae (pneumococcus), Neisseria meningitides (meningococcus) and group B streptococcus (GBS), cause a major proportion of disease in early childhood. Native PS vaccines are immunogenic and provide protection against disease in healthy adults but do not induce immunological memory. PSs are T-cell-independent antigens and do not elicit antibodies in infants and young children, but by conjugating PS to proteins they become T-cell dependent and immunogenic at an early age. Despite excellent efficacy of PS-protein conjugate vaccines against invasive disease, protection against mucosal infections such as pneumococcal otitis media has been less efficacious. Circulating PS-specific antibodies may protect against infections at mucosal sites, but mucosal immunoglobulin A antibodies may also contribute significantly to protection against mucosal infections. Mucosal immunization of experimental animals with conjugate vaccines against Hib, pneumococcus, meningococcus and GBS induces systemic and mucosal immune responses, which provide protection against carriage, otitis media and invasive disease in a variety of challenge models, providing new means for protection against encapsulated bacteria. In addition, mucosal immunization of neonatal mice with a pneumococcal conjugate and the nontoxic adjuvant LT-K63 has been superior to parenteral immunization in eliciting protective antibodies and PS-specific memory, and thus circumventing the limitations of antibody responses to PS that are responsible for enhanced susceptibility of neonates and infants to infections caused by encapsulated bacteria. Through T-cell dependent enhanced immunogenicity of PS-protein conjugate vaccines, mucosal immunization could be an attractive approach for early life immunization against encapsulated bacteria.en
dc.language.isoenen
dc.publisherBlackwell Scientific Publicationsen
dc.relation.urlhttp://www.blackwell-synergy.com/doi/full/10.1046/j.1365-3083.2003.01292.xen
dc.subject.meshAdulten
dc.subject.meshBacterial Vaccinesen
dc.subject.meshChilden
dc.subject.meshHaemophilus Infectionsen
dc.subject.meshHaemophilus Vaccinesen
dc.subject.meshHumansen
dc.subject.meshImmunity, Mucosalen
dc.subject.meshInfanten
dc.subject.meshNeisseriaceae Infectionsen
dc.subject.meshPneumococcal Infectionsen
dc.subject.meshPneumococcal Vaccinesen
dc.subject.meshPolysaccharides, Bacterialen
dc.subject.meshResearch Support, Non-U.S. Gov'ten
dc.subject.meshRespiratory Tract Infectionsen
dc.subject.otherVaccines, Conjugateen
dc.titleMucosal vaccination against encapsulated respiratory bacteria--new potentials for conjugate vaccines?en
dc.typeArticleen
dc.identifier.journalScandinavian journal of immunologyen
dc.format.digYES-
All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.